The same is true for metastatic PCa patients, where the mutation burden involving androgen receptors is 10–20% of metastatic castrate-resistant PCa patients; another tumour-related gene, such as PI3KCA, accounts for 6% of metastatic patients, or germline/somatic mutation of DNA damage repair genes that are found in 15–30% of metastatic patients, half of which is of germline origin [19]. The gene discussed is AR; the disease is posterior cortical atrophy.